英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Biens查看　Biens　在百度字典中的解释百度英翻中〔查看〕
Biens查看　Biens　在Google字典中的解释Google英翻中〔查看〕
Biens查看　Biens　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Home - Viking Therapeutics
    Developing novel therapeutics for metabolic and endocrine disorders Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives Viking’s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors
  • Viking Therapeutics - Overview
    Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential
  • Management - Viking Therapeutics
    Prior to Viking, he was VP of Finance and Chief Accounting Officer at Trius Therapeutics, Inc , a subsidiary of Cubist Pharmaceuticals, Inc , a pharmaceutical company, following Cubist’s acquisition of Trius Prior to Trius, he was Director of Lilly Research Labs Finance at Eli Lilly and Company, a pharmaceutical company
  • Viking Therapeutics - Press Releases
    Viking Therapeutics, Inc ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced
  • Viking Therapeutics - Stock Quote
    Currency in USD Quote data delayed by at least 15 minutes
  • Viking Therapeutics to Participate at Upcoming Investor Conferences
    SAN DIEGO, March 5, 2026 PRNewswire -- Viking Therapeutics, Inc ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences
  • Viking Therapeutics InvestorRoom - Corporate Presentation
    Contact info@vikingtherapeutics com 9920 Pacific Heights Blvd, Suite 350 San Diego, CA 92121 858-704-4660
  • Overview - Viking Therapeutics
    We have a pipeline of novel, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives Viking’s clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and
  • Contact - Viking Therapeutics
    Contact Viking Therapeutics, Inc 9920 Pacific Heights Blvd, Suite 350 San Diego, CA 92121 858-704-4660 General Information
  • Viking Therapeutics - Webcasts Presentations
    Contact info@vikingtherapeutics com 9920 Pacific Heights Blvd, Suite 350 San Diego, CA 92121 858-704-4660





中文字典-英文字典  2005-2009